Theriva Biologics (NYSEAMERICAN:TOVX) Releases Quarterly Earnings Results

Theriva Biologics (NYSEAMERICAN:TOVX) announced its quarterly earnings data on Tuesday. The company reported ($0.07) earnings per share for the quarter, FiscalAI reports.

Theriva Biologics Price Performance

Shares of Theriva Biologics stock opened at $0.23 on Tuesday. Theriva Biologics has a 52 week low of $0.16 and a 52 week high of $0.86. The company has a current ratio of 1.63, a quick ratio of 1.63 and a debt-to-equity ratio of 0.11. The stock has a market cap of $7.79 million, a PE ratio of -0.01 and a beta of 1.11. The company’s 50-day moving average price is $0.24 and its two-hundred day moving average price is $0.24.

Hedge Funds Weigh In On Theriva Biologics

An institutional investor recently raised its position in Theriva Biologics stock. Geode Capital Management LLC increased its holdings in Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) by 651.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 212,087 shares of the company’s stock after purchasing an additional 183,878 shares during the quarter. Geode Capital Management LLC owned 0.63% of Theriva Biologics worth $45,000 at the end of the most recent quarter. Institutional investors own 6.17% of the company’s stock.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.